Over the past five days, individual investors have net purchased 81,551 shares, while foreigners and institutions have net sold 180,843 shares and net purchased 87,042 shares, respectively.
On July 10, Celltrion became a market topic with the announcement of a "115.6 billion KRW contract for the contract manufacturing of a migraine treatment drug."

※ This article was generated in real-time by an automated article creation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
![Clutching a Stolen Dior Bag, Saying "I Hate Being Poor but Real"... The Grotesque Con of a "Human Knockoff" [Slate]](https://cwcontent.asiae.co.kr/asiaresize/183/2026021902243444107_1771435474.jpg)
